Dual integrin αvβ3 and αvβ5 blockade attenuates cardiac dysfunction by reducing fibrosis in a rat model of doxorubicin-induced cardiomyopathy

• Published in: Scandinavian cardiovascular journal : SCJ Vol. 55; no. 5; pp. 287 - 296
• Main Authors: Sui, Shi, Hou, Yang
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 01.10.2021
• Subjects: Animals; Cardiomyopathies - chemically induced; Cardiomyopathies - epidemiology; Cilengitide; Disease Models, Animal; doxorubicin; Doxorubicin - toxicity; Fibrosis - prevention & control; heart failure; integrin; Integrin alphaVbeta3 - antagonists & inhibitors; Male; myocardial fibrosis; Rats; Receptors, Vitronectin - antagonists & inhibitors; heart failure; Cilengitide; doxorubicin; integrin; myocardial fibrosis
• ISSN: 1401-7431; 1651-2006
• DOI: 10.1080/14017431.2021.1955960

Objective: The present study aimed to evaluate the protective role of cilengitide (CGT), an integrin αvβ3 and αvβ5 inhibitor, on doxorubicin (DOX)-induced myocardial fibrosis and cardiac dysfunction in a rat model. Methods. Forty male rats were randomly divided into four groups: DOX (n = 12), intraperitoneal (i.p.) injection of DOX 0.8 ∼ 1.0 mg/kg three times a week for up to 6 weeks, then saline i.p. three times a week for another 3 weeks; CGT (n = 8), CGT 10 mg/kg, i.p. three times a week for 9 weeks; DOX + CGT (n = 12), DOX and CGT co-administration as above for 6 weeks, then CGT alone for another 3 weeks; Control (n = 8), saline i.p. three times a week for 9 weeks. Echocardiography, serum procollagen I C-terminal propeptide (PICP) procollagen III N-terminal propeptide (PIIINP) and C telopeptide type I (CTX-I) were evaluated at baseline and 3, 6 and 9 weeks after initial DOX administration for all surviving rats. The heart tissues were then harvested for myocardial hydroxyproline (HYP) evaluation, qRT-PCR, and western blotting. Results. CGT attenuated DOX-induced eccentric remodeling by improving relative wall thickness at the 9th week. CGT also improved systolic function at the 9th week and diastolic function at the 6th and 9th week. CGT reduced myocardial HYP and serum PICP, PIIINP, CTX-I, and the PICP/PIIINP ratio. RT-PCR and western blot showed that CGT blocked the TGF-β1/SMAD3 pathway and mitigating extracellular matrix turnover. Conclusions. CGT exerted a cardioprotective effect against doxorubicin-induced fibrosis and improved cardiac function.